Table 1.
Clinical characteristics and biochemical assessments of the patients included in the study.
| CVD (n = 76) | Non CVD (n = 16) | P value | |
|---|---|---|---|
| Age (years) | 65.3 ± 7.4 | 63.2 ± 9.3 | 0.38 |
| Sex (M/F) | 59 / 17 | 10/6 | 0.22 |
| Smoker (%) | 77.6 | 75.0 | 0.75 |
| BMI (kg/m2) | 27.5 ± 3.6 | 29.4 ± 3.2 | 0.06 |
| HT (%) | 77.6 | 56.3 | 0.11 |
| DM (%) | 43.4 | 31.3 | 0.42 |
| Pharmacological treatment | |||
| Antiaggregants (%) | 91.0 | 16.7 | < 0.0001 |
| Beta-blockers (%) | 27.6 | 16.7 | 0.34 |
| ACEI/ARA2 (%) | 51.3 | 25.0 | < 0.05 |
| CCB (%) | 25.0 | 16.7 | 0.35 |
| Statins (%) | 85.5 | 8.3 | < 0.0001 |
| Laboratory data | |||
| eGFR (mL/min/1.73 m2) | 89.6 ± 13.2 | 89.8 ± 26.7 | 0.61 |
| Creatinine (mg/dL) | 0.84 ± 0.2 | 0.93 ± 0.5 | 0.48 |
| Albumin (g/dL) | 3.8 ± 0.5 | 3.9 ± 0.6 | 0.43 |
| Calcium (mg/dL) | 9.1 ± 0.5 | 9.3 ± 0.9 | < 0.05 |
| Phosphorus (mg/dL) | 3.6 ± 0.5 | 3.5 ± 0.9 | 0.67 |
| Uric acid (mg/dL) | 5.9 ± 1.4 | 6.1 ± 1.5 | 0.63 |
| Glucose (mg/dL) | 117.3 ± 37.1 | 131.2 ± 39.4 | 0.21 |
| Cholesterol (mg/dL) | 165.4 ± 48.7 | 190.2 ± 29.9 | 0.12 |
| HDL (mg/mL) | 43.2 ± 11.2 | 47.5 ± 14.6 | 0.67 |
| LDL (mg/dL) | 88.2 ± 37.2 | 121.0 ± 26.1 | < 0.01 |
| Neutrophils (/mL) | 7494 ± 5081 | 8287 ± 5815 | 0.50 |
| Lymphocytes (/mL) | 2020 ± 998.2 | 1894 ± 729.9 | 0.91 |
| Serum inflammatory markers | |||
| NLR | 3.8 ± 1.9 | 2.8 ± 1.2 | 0.21 |
| CRP (mg/L) | 2.9 ± 2.6 | 1.9 ± 0.9 | 0.38 |
| TNFα (pg/mL) | 1.04 (0.80–1.44) | 1.37 (0.90–1.98) | 0.11 |
| IL10 (pg/mL) | 3.93 (0.61–10.13) | 10.38 (7.52–30.20) | < 0.001 |
| TNFα/IL10 | 0.28 (0.10–1.62) | 0.11 (0.02–0.27) | < 0.01 |
| sKL (pg/mL) | 507.7 (361.4–656.6) | 1007 (590.4–1883) | < 0.01 |
ACEI/ARA2 Angiotensin converting enzyme inhibitor/angiotensin receptor antagonist 2; BMI Body mass index; CCB Calcium channels blockers; CRP C-reactive protein; DM Diabetes mellitus; eGFR Estimated glomerular filtration rate; HDL High-density lipoprotein; HT hypertension; IL10 Interleukin 10; LDL Low-density lipoprotein; NLR Neutrophil-to-lymphocyte ratio; TNFα Tumor necrosis factor alpha.